Table 2.
Demographic and Pathological Data of the Cyproterone acetate (CPA) Cohort Compared With the Control Cohort
| CPA cohort | Control cohort | Chi2 | Degree of freedom | P | |
|---|---|---|---|---|---|
| Demographics data | |||||
| Total cases | 30 | 150 | |||
| Age, mean (range), y | 50 (29–68) | 58 (22–90) | |||
| Sex (F:M) | 29:1 | 95:55 | |||
| Localization | |||||
| Skull base | 26 (86.7%) | 73 (48.7%) | 13.10 | 1 | <.001 |
| Convexity | 4 (13.3%) | 77 (51.3%) | |||
| AKT1 status | |||||
| Mutated | 5 (16.7%) | 9 (6%) | 2.62 | 1 | .10 |
| Wild-type | 25 (83.3%) | 141 (94%) | |||
| PIK3CA status | |||||
| Mutated | 5 (16.7%) | 7 (4.7%) | 4.02 | 1 | .045 |
| Wild-type | 25 (83.3%) | 143 (95.3%) | |||
| PIK3CA/AKT1 pathway status | |||||
| Mutated | 10 (33.3%) | 16 (10.7%) | 8.64 | 1 | .003 |
| Wild-type | 20 (66.7%) | 134 (89.3%) | |||
| CAS | |||||
| 0 | 10 (40%) | 55 (36.7%) | 10.35 | 5 | .06 |
| 1–2 | 14 (56%) | 56 (37.3%) | |||
| 3–4 | 0 | 15 (10%) | |||
| 5–6 | 0 | 17 (11.3%) | |||
| 7–8 | 0 | 6 (4%) | |||
| 9 | 1 (4%) | 1 (0.7%) | |||
| WHO grade | |||||
| Grade I | 27 (90%) | 104 (69.3%) | 5.54 | 2 | .06 |
| Grade II | 3 (10%) | 41 (27.3%) | |||
| Grade III | 0 | 5 (3.4%) | |||
| Histopathology | |||||
| Chordoid | 1 (3.3%) | 0 | 23.74 | 5 | <.001 |
| Meningothelial | 19 (63.4%) | 38 (42.7%) | |||
| Metaplastic | 1 (3.3%) | 0 | |||
| Microcystic | 3 (10%) | 0 | |||
| Transitional | 6 (20%) | 45 (50.6%) | |||
| Fibroblastic | 0 | 6 (6.7%) |